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Abstract 
We report a case of facial diffuse large B-cell lymphoma (DLBCL) associated with recurrent 
metastasis in the heart and other sites in a 76-year-old Japanese woman. Initially, she 
developed DLBCL in her left upper eyelid that spread into the left orbit (Ann Arbor 
classification stage I). The lesion went into clinical regression after 4 cycles of rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy followed by 
radiotherapy. More than 3 years later, the lymphoma recurred in her facial skin, together 
with metastases in the mediastinal lymph nodes and the heart; the tumor in the heart was 
successfully detected by PET/CT and cardiac MRI. To treat the recurrent lesions, we 
performed a salvage chemotherapy regimen comprising prednisone, etoposide, 
procarbazine, and cyclophosphamide, which successfully induced tumor regression. 
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Introduction 
Detecting cardiac metastasis of malignant tumors is not easy, with most such cases 
diagnosed only at autopsy. Thus, it is rare that cardiac metastasis is correctly diagnosed 
after successful primary treatment with first-line chemotherapy. We recently 
encountered an elderly female patient suffering a recurrence of diffuse large B-cell 
lymphoma (DLBCL) involving the forehead, left eyelid, and orbit, and in whom heart 
metastasis was detected by PET/CT and cardiac MRI. She was successfully treated with 
the salvage oral combination chemotherapy regimen of prednisone, etoposide, 
procarbazine, and cyclophosphamide (PEP-C). 
Case Report 
A 76-year-old female patient presented at our hospital in July 2006 with swelling of the left upper 
eyelid, which was subsequently diagnosed histopathologically as DLBCL expressing CD20 antigen. 
MRI revealed extension of the tumor from the left upper eyelid into the orbital cavity, but CT imaging 
showed no other lesions. The tumor was graded as stage I according to the Ann Arbor classification 
[1], and the patient was treated accordingly with the standard chemotherapy regimen of 4 cycles of 
rituximab (Rit) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). She 
subsequently underwent radiotherapy to the left orbit (40 Gy/20 fractions). Following this initial 
treatment, no lesions were detected on imaging studies and the tumor was declared to be completely 
resolved. 
There was no recurrence during the subsequent 3 years. However, in December 2010, our patient 
noted the development of red papules on her forehead, which spread to the left eyelid. 
Histopathologically, the lesions were again diagnosed as DLBCL, indicating a late recurrence. A 
PET/CT scan of fluorodeoxyglucose (FDG) uptake demonstrated additional tumors in the forehead 
and nasal cavity connected to the lesion on the left eyelid. Abnormal uptake was also found in the 
mediastinal lymph nodes and the heart (fig. 1); these findings were confirmed by CT (fig. 2). Cardiac 
MRI revealed the presence of abnormal masses in the right ventricular wall together with an 
infiltration of the right atrium, aortic root, and tricuspid valve (fig. 3). A recurrence of the facial 
DLBCL accompanied by metastasis to the heart and mediastinal lymph nodes was therefore 
diagnosed. Interestingly, the patient showed a good general state and no cardiac functional 
abnormalities by echocardiography or electrocardiogram. 
Considering her age, the patient was started on PEP-C salvage chemotherapy according to Coleman 
et al.’s regimen [2]. This treatment consisted of daily oral administration of prednisone 20 mg after 
breakfast, cyclophosphamide 50 mg after lunch, etoposide 50 mg after dinner, and procarbazine 50 
mg at bedtime, and it was continued until the white blood cell (WBC) count dropped below 3.0 × 109/l 
(fig. 4). Within one week, almost all of the forehead papules regressed, and on day 18 the metastatic 
cardiac tumor was also markedly reduced in size (fig. 3). At this stage, CD20 antigen expression 
remained and residual tumor was apparent, prompting the start of a new combined therapy of Rit 
plus the PEP-C regimen from day 22 (fig. 4). On day 37, PET/CT imaging showed partial remission of 
the residual tumor (fig. 1), although the patient’s WBC count remained above 3.0 × 109/l. The daily 
oral medication was therefore continued until day 37. At this time, Japan was struck by the Great 
Eastern Earthquake, and all treatment was withheld until completion of the necessary infrastructure 
reconstruction. On day 56, the PEP-C regimen was reinstituted according to the maintenance phase of 
Coleman et al.’s regimen [2]. At the beginning of this maintenance phase, the dosing frequency was 
planned over 14 consecutive days with a one-week rest to constitute a Rit tri-weekly administration. 
On day 112, enhanced CT imaging showed a remarkable reduction in size of the numerous 
mediastinal lymph nodes together with near disappearance of the cardiac tumor (fig. 2). The patient 
finished the Rit therapy after 6 cycles of administration, and continued the PEP-C regimen as 
maintenance therapy.  
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Discussion 
In general, cardiovascular symptoms related to malignant lymphoma tend to appear 
only at the end stage of the disease [3, 4]. However, we report a unique case herein, 
whereby despite the presence of heart metastasis in the recurrent stage of DLBCL, the 
patient maintained a good general condition without noticeable cardiovascular 
symptoms. Moreover, we could only reach our final diagnosis thanks to the advanced 
nature of current diagnostic medical imaging technology such as echocardiography, 
PET/CT, CT, and cardiac MRI. 
The incidence range of heart metastasis is 1.5–20.6% in patients with malignancies 
[5–8], although such metastatic tumors, and particularly those of malignant lymphoma, 
are mostly asymptomatic clinically and rarely diagnosed within the lifetime of the 
patient. Rosenberg et al. [9] reported that among 277 autopsy cases of cardiac 
malignant tumors, 63 had malignant lymphoma, indicating that its incidence is not rare, 
and none were diagnosed in a living patient. When Rafajlovski et al. [10] performed 
11,403 autopsies from 1972 to 2004, malignant tumor was diagnosed in 2,928 of the 
autopsies and in 79 (2.7%) of these cases, heart metastasis was found. Even with this 
large number of patients, the diagnosis of heart metastasis was made only in 5 cases 
during the patients’ lifetime. The highest frequency of heart metastasis was reported in 
cases of pulmonary carcinoma (18 cases), followed by leukemia, and then malignant 
lymphoma (8 cases each). According to Roberts et al. [3], only 5 of their 48 autopsied 
cases of malignant lymphoma had heart involvement that presented clinically with 
cardiovascular symptoms in their patients’ lifetime. However, these symptoms were 
highly variable including pericarditis, pericardial effusion, angina, congestive heart 
failure, arrhythmia, and non-infectious endocarditis. Hanfling [11] indicated that even 
the cause of arrhythmia was dependent on the site influencing the conduction system 
of the heart rather than on tumor size. In addition, the manifestation of these 
cardiovascular symptoms tends to appear mostly at the end stage of the disease [3, 4]. 
The metastatic pathways of malignant lymphoma to the heart consist of 
hematogenous metastasis, direct invasion, and lymphatic metastasis [11], with the first 
mechanism being the most common. In the case of lymphatic metastasis, the tumor is 
thought to reach the heart by a retrograde flow through mediastinal and 
tracheobronchial lymphatic channels because the superficial lymph channels of the 
heart were filled with malignant cells in those reported cases of carcinomatous 
lymphangitis [3, 4]. In our present case, hematogenous metastasis is the most plausible 
causative mechanism because the primary lesion was found in the left eyelid. However, 
we cannot rule out the possibility of lymphatic metastasis from the mediastinal and 
tracheobronchial lymph nodes that showed swelling at the recurrence. 
Finally, our literature search for cardiac metastasis of DLBCL that was detected 
during the patient’s lifetime and treated with salvage chemotherapy revealed only a 
few reports. The most frequently reported cases involve the primary cardiac DLBCL or 
DLBCL with cardiac metastasis at the time of initial diagnosis. In these cases, CHOP or 
R-CHOP chemotherapy was employed. Coleman et al. [2] reported using PEP-C oral 
combination chemotherapy for 75 patients with DLBCL, 52 of whom showed complete 
or partial resolution despite one or more prior therapies. Our present case represents a 
successful response to PEP-C oral combination chemotherapy that was conducted as 
salvage chemotherapy for DLBCL in the elderly. The regimen proved to be effective and  
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safe in the present elderly patient, and we therefore recommend this PEP-C regimen as 
salvage treatment for cardiac metastasis of DLBCL. 
 
 
 
 
 
 
Fig. 1. Contrast PET/CT. a, b Abnormal uptake of FDG demonstrated the presence of tumor in the 
numerous mediastinal lymph nodes and in the heart. c, d On day 37 after the introduction of 
chemotherapy, FDG uptake had virtually disappeared. 
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Fig. 2. Contrast-enhanced CT. a, b After the initial treatment, there were no abnormal findings. c, d In 
January 2011, there was a swelling of the mediastinal lymph nodes and an abnormal mass in the right 
ventricular wall. e, f On day 112 after the introduction of salvage chemotherapy, no swelling of the 
mediastinal lymph nodes was detected and the abnormal cardiac mass was diminished in size. 
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Fig. 3. Contrast cardiac MRI. a, b Abnormal mass in the right ventricular wall invading the right 
atrium, aortic root, and tricuspid valve. c, d On day 18 after the introduction of chemotherapy, the 
cardiac tumor remained, but had decreased in size. 
 
 
 
Fig. 4. Patient progress during treatment. The PEP-C regimen consisted of daily oral administration 
of prednisone 20 mg after breakfast, cyclophosphamide 50 mg after lunch, etoposide 50 mg after 
dinner, and procarbazine 50 mg at bedtime. The dosing frequency in the maintenance phase 
comprised administration for 14 consecutive days with a one-week rest, with the medications and 
doses given per day held constant according to the introduction of the PEP-C regimen. The frequency 
of Rit administration was tri-weekly from day 22. LDH = Lactic dehydrogenase (IU/l); sIL-2R = 
interleukin 2 receptor, soluble (U/ml). 
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